These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 15199342)
1. Can change in high-density lipoprotein cholesterol levels reduce cardiovascular risk? Dean BB; Borenstein JE; Henning JM; Knight K; Merz CN Am Heart J; 2004 Jun; 147(6):966-76. PubMed ID: 15199342 [TBL] [Abstract][Full Text] [Related]
2. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments. Evans M; Roberts A; Davies S; Rees A Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326 [TBL] [Abstract][Full Text] [Related]
3. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. Cziraky MJ; Watson KE; Talbert RL J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279 [TBL] [Abstract][Full Text] [Related]
5. The role of non-HDL cholesterol in risk stratification for coronary artery disease. Rana JS; Boekholdt SM; Kastelein JJ; Shah PK Curr Atheroscler Rep; 2012 Apr; 14(2):130-4. PubMed ID: 22203405 [TBL] [Abstract][Full Text] [Related]
6. HDL-C: role as a risk modifier. Barter P Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280 [TBL] [Abstract][Full Text] [Related]
7. High-density lipoprotein cholesterol as a therapeutic target to reduce cardiovascular events. Fonarow GC; Watson KE Am Heart J; 2004 Jun; 147(6):939-41. PubMed ID: 15199335 [No Abstract] [Full Text] [Related]
8. Emerging strategies and agents to lower cardiovascular risk by increasing high density lipoprotein cholesterol levels. Greenfeder S Curr Med Chem; 2009; 16(2):144-56. PubMed ID: 19149567 [TBL] [Abstract][Full Text] [Related]
9. Lipoprotein(a), cardiovascular disease, and contemporary management. Jacobson TA Mayo Clin Proc; 2013 Nov; 88(11):1294-311. PubMed ID: 24182706 [TBL] [Abstract][Full Text] [Related]
10. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465 [TBL] [Abstract][Full Text] [Related]
12. HDL-C levels and revascularization procedures in coronary heart disease patients treated with statins to target LDL-C levels. Elis A; Pereg D; Froom P; Lishner M; Segev D; Hermoni D Clin Cardiol; 2011 Sep; 34(9):572-6. PubMed ID: 21887688 [TBL] [Abstract][Full Text] [Related]
13. The beneficial effects of raising high-density lipoprotein cholesterol depends upon achieved levels of low-density lipoprotein cholesterol during statin therapy: Implications for coronary atheroma progression and cardiovascular events. Puri R; Nissen SE; Shao M; Kataoka Y; Uno K; Kapadia SR; Tuzcu EM; Nicholls SJ Eur J Prev Cardiol; 2016 Mar; 23(5):474-85. PubMed ID: 25691546 [TBL] [Abstract][Full Text] [Related]
14. The relative role of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in coronary artery disease: evidence from large-scale statin and fibrate trials. Sacks FM Am J Cardiol; 2001 Dec; 88(12A):14N-18N. PubMed ID: 11788125 [TBL] [Abstract][Full Text] [Related]
15. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. Reiner Z Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901 [TBL] [Abstract][Full Text] [Related]
16. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial. Stender S; Schuster H; Barter P; Watkins C; Kallend D; Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130 [TBL] [Abstract][Full Text] [Related]
19. HDL hypothesis: where do we stand now? Tariq SM; Sidhu MS; Toth PP; Boden WE Curr Atheroscler Rep; 2014 Apr; 16(4):398. PubMed ID: 24619460 [TBL] [Abstract][Full Text] [Related]
20. HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol. Tani S; Nagao K; Hirayama A Am J Cardiovasc Drugs; 2011 Dec; 11(6):411-7. PubMed ID: 22149320 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]